- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Health Canada Shares Fiscal Year Data for Medical Cannabis
The Canadian agency shared the latest results of cannabis production and consumption, along patient registration under its medical program.
The Canadian medical agency tasked with tracking and regulating the use and production of cannabis in the country announced new numbers on Monday (July 9) in terms of medical patients of the drug.
As part of the market information Health Canada tracks and publishes for cannabis, the agency now offers data on a monthly basis for its fiscal quarters, with the most recent one being January to March.
Based on the data, patient registration under the Access to Cannabis for Medical Purposes Regulations (ACMPR) program has continued to increase. At the end of March 2018, the fiscal fourth quarter for Health Canada, data showed a total number of patient registrations of 296,702.
According to cannabis analyst with 420 Investor Alan Brochstein, the growth last quarter represents quarterly growth of 10.1 percent and annual growth of 79.9 percent.
Brochstein called the increment in legal cannabis patients “robust” but highlighted it was the slowest quarterly growth since the origin of the program. He said these figures represent a maturation of the medical cannabis program and “perhaps some hesitancy among potential patients who will just wait for legalization.
Cannabis oils continue market dominance in legal medical landscape
The federal agency also offered an update on the amount of legal cannabis patients had access to during the most recent fiscal quarter.
Cannabis oils continued its growth path while dried flower remained steady with 6,610 kilograms sold during the fourth fiscal quarter. Oils amounted to 10,326 kilograms, an 11 percent increase from the previous quarter according to Brochstein.
During the fiscal 2017-2018 year, Health Canada reported 33,463 kilograms of cannabis oil sold to patients, while the amount of dried flower sold during the fiscal year was 24,753 kilograms.
Licensed producers (LP) of cannabis in Canada reported a total saved inventory worth 44,179 kilograms of dried cannabis and 15,727 litres at the end of March.
Investor takeaway
Despite the limited offerings of legal cannabis product for consumers at the time of this data, investors are able to see the demand for cannabis oils surpases dried flower in the medical space as consumers seek more variety for treatments.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.